- Price
- $89.59
- Day
- +4.16%
- Mkt Cap
- $12.62B
- 52W Range
- $15.01 – $95.49
- Volume
- 2.03M
- Beta
- 1.29
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Arrowhead Pharmaceuticals NASDAQ: ARWR reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (FCS).
Read full article
California State Teachers Retirement System raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 21.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,313 shares of the biotechnology company's stock after acquiring an additional 25,941 shares during
Read full article
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company is hosting a conference call today, August 4, 2026, at 4:30 p.m. ET to discuss the results. “The recent period for Arrowhead included transformational events that support continued growth,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We recently announced topline results from.
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has signed an agreement with an undisclosed third party to acquire a U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Priority Review Voucher (PRV). The company intends to utilize the PRV for its upcoming Supplemental New Drug Application (sNDA) submission for plozasiran, anticipated before the end of 2026, to seek approval to expand the approved indication to include patients.
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 16, 2026, the Company's Board of Directors approved “inducement” grants to 95 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 112,794 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest.
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol (LDL-C) and early onset cardiovascular disease. Arrowhe.
Read full article
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of z
Read full article
Affinity Asset Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 185.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 200,000 shares of the biotechnology company's stock after acquiring an additional 130,000 shares during the quarter.
Read full article
California Public Employees Retirement System purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 257,133 shares of the biotechnology company's stock, valued at approximately $16,122,000. California Public Employees
Read full article
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is associated with repeated hospital admissions and can be fatal. SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and m.
Read full article
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Read full article